{"id":59493,"date":"2024-09-16T12:00:32","date_gmt":"2024-09-16T12:00:32","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/16\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/"},"modified":"2024-09-16T12:00:32","modified_gmt":"2024-09-16T12:00:32","slug":"angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/","title":{"rendered":"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024"},"content":{"rendered":"<div>\n<p><em>Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets<\/em><\/p>\n<p align=\"left\">WOODLAND HILLS, Calif., Sept.  16, 2024  (GLOBE NEWSWIRE) &#8212; Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2118 for the treatment of osteoporosis will be presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (ASBMR) September 27-30, 2024, in Toronto, ON, Canada. Preclinical and clinical abstracts for AGA2118 were selected by conference organizers as highlights of the meeting.<\/p>\n<p align=\"justify\"><strong><u>Details of the presentations are as follows:<\/u><\/strong><\/p>\n<p align=\"justify\"><strong>Title: <\/strong>AGA2118, a Bispecific Antibody Neutralizing both Sclerostin and DKK1, Increased Bone Formation, Decreased Bone Resorption, and Led to Rapid BMD Gains in a First in Human, Single- and Multiple-Dose, Placebo-Controlled Randomized Study<br \/><strong>Format: <\/strong>Oral Presentation<br \/><strong>Session Date and Time: <\/strong>Friday, Sept 27, 2024, 11:00 \u2013 12:15 pm <br \/><strong>Abstract Number: <\/strong>1011<\/p>\n<p align=\"justify\"><strong>Title: <\/strong>Long-Term Effects of AGA2118, a Bispecific Antibody that Neutralizes Both Sclerostin and DKK1, on Bone Formation and Bone Resorption Markers in Cynomolgus Monkeys<br \/><strong>Format: <\/strong>Poster Session<br \/><strong>Session Date and Time: <\/strong>Friday, Sept 27, 2024, 5:30 \u2013 7:30 pm; Saturday, Sept 28, 2024, 2:15 \u2013 3:45 pm<br \/><strong>Abstract Number: <\/strong>109<\/p>\n<p align=\"justify\"><strong>Title: <\/strong>Preclinical and Clinical Pharmacokinetics of AGA2118, A Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1 (DKK1), for the Treatment of Osteoporosis<br \/><strong>Format: <\/strong>Poster Session<br \/><strong>Session Date and Time: <\/strong>Saturday, Sept 28, 2024, 2:15 \u2013 3:45 pm<br \/><strong>Abstract Number: <\/strong>396<\/p>\n<p align=\"justify\"><strong>Title: <\/strong>AGA2118, a Bispecific Antibody Neutralizing Both Sclerostin and DKK1, Increased Bone Formation and Decreased Bone Resorption, Leading to a Rapid Increase in Bone Mass and Strength in an Ovariectomized Cynomolgus Monkey Model<br \/><strong>Format: <\/strong>Oral Presentation<br \/><strong>Session Date and Time: <\/strong>Sunday, Sept 29, 2024, 11:15 \u2013 12:30 pm<br \/><strong>Abstract Number: <\/strong>1071<\/p>\n<p><strong>About Osteoporosis<\/strong><\/p>\n<p>Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis has become a global epidemic, especially for older women, due to an aging population and longer life expectancies. Estimates indicate that more than 200 million patients worldwide suffer from osteoporosis.<\/p>\n<p>Although there are a number of approved therapies for osteoporosis, limitations remain regarding the efficacy and\/or safety of each of these options. Research also indicates that most severely osteoporotic individuals do not receive a bone-active agent. As a result, a large unmet medical need remains for the development of new osteoporosis therapies.<\/p>\n<p><strong>About AGA2118<\/strong><\/p>\n<p>AGA2118 is a Sclerostin x DKK1 bispecific antibody in clinical development for the treatment of osteoporosis. Sclerostin and DKK1 are two critical, negative regulators of WNT signaling in osteoblasts and bone metabolism. By targeting both proteins, AGA2118 is thought to prevent compensatory increase of either agent, aiming to improve magnitude of bone mineral density gains in osteoporotic patients. Angitia wholly owns the bispecific antibody.<\/p>\n<p><strong>About Angitia Biopharmaceuticals<\/strong><\/p>\n<p>Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team&#8217;s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.<\/p>\n<p>Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VIOGRnV-HD2eHuvuADygnSUcby0tr022TCoDYk4SA5-3rbb7fZyunfQovhkxyavslZbUdgxrcHdyyNrieAiiDHh_-mzMtJuomagaBdpGMHo=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.angitiabio.com\">www.angitiabio.com<\/a>.<\/p>\n<p><strong>Investor &amp; Media Contact:<\/strong><\/p>\n<p>William Windham<br \/>Solebury Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VOcPsRyrq8O2WL2ASg92dhMK6o1O8y1Elxg7kCypSd3amqx3wq6Q430_IGLUMAO5UTl5yfS0ALgSEz7arT01F3THabUK1hBfcQteE9QMs806juVajz_BkRtw-UPhRICd\" rel=\"nofollow noopener\" target=\"_blank\" title=\"wwindham@soleburystrat.com\">wwindham@soleburystrat.com<\/a><br \/>646-378-2946<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release is prepared by Angitia (the \u201cCompany\u201d, \u201cWe\u201d) for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as \u201canticipate\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cbelieve\u201d, \u201ccontinue\u201d, \u201ccould\u201d, \u201cpotential\u201d, \u201cmay\u201d, \u201cwill\u201d, \u201cgoal\u201d or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.<\/p>\n<p>These forward-looking statements involve substantial known and unknown risks, uncertainties, and other factors that are beyond the Company\u2019s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.<\/p>\n<p>Except as expressly required by law, the Company and\/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjU1MjU4M2EtMDlhNy00NjlmLWI0M2YtYmY0OTgyZjA2YTVhLTEyNzUzNDI=\/tiny\/Angitia-Biopharmaceuticals.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets WOODLAND HILLS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) &#8212; Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2118 [&#8230;]\n","protected":false},"author":1,"featured_media":59494,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59493","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024\" \/>\n<meta property=\"og:description\" content=\"Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets WOODLAND HILLS, Calif., Sept. 16,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-16T12:00:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Angitia-Biopharmaceuticals.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024\",\"datePublished\":\"2024-09-16T12:00:32+00:00\",\"dateModified\":\"2024-09-16T12:00:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\"},\"wordCount\":735,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\",\"name\":\"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-09-16T12:00:32+00:00\",\"dateModified\":\"2024-09-16T12:00:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/","og_locale":"en_US","og_type":"article","og_title":"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024","og_description":"Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets WOODLAND HILLS, Calif., Sept. 16,","og_url":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-09-16T12:00:32+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Angitia-Biopharmaceuticals.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024","datePublished":"2024-09-16T12:00:32+00:00","dateModified":"2024-09-16T12:00:32+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/"},"wordCount":735,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/","url":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/","name":"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-09-16T12:00:32+00:00","dateModified":"2024-09-16T12:00:32+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/angitia-biopharmaceuticals-to-present-data-on-aga2118-for-osteoporosis-at-asbmr-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/59493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=59493"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/59493\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/59494"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=59493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=59493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=59493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}